CN115551875A - 用于酪氨酸酶介导的位点特异性蛋白质缀合的系统和方法 - Google Patents

用于酪氨酸酶介导的位点特异性蛋白质缀合的系统和方法 Download PDF

Info

Publication number
CN115551875A
CN115551875A CN202180033900.4A CN202180033900A CN115551875A CN 115551875 A CN115551875 A CN 115551875A CN 202180033900 A CN202180033900 A CN 202180033900A CN 115551875 A CN115551875 A CN 115551875A
Authority
CN
China
Prior art keywords
tco
composition
functionalized
protein
tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180033900.4A
Other languages
English (en)
Chinese (zh)
Inventor
A·M·埃尔森利
P·G·霍尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN115551875A publication Critical patent/CN115551875A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
CN202180033900.4A 2020-05-05 2021-05-05 用于酪氨酸酶介导的位点特异性蛋白质缀合的系统和方法 Pending CN115551875A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063020405P 2020-05-05 2020-05-05
US63/020,405 2020-05-05
PCT/US2021/030905 WO2021226247A1 (en) 2020-05-05 2021-05-05 Systems and methods for tyrosinase-mediated site-specific protein conjugation

Publications (1)

Publication Number Publication Date
CN115551875A true CN115551875A (zh) 2022-12-30

Family

ID=76160021

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180033900.4A Pending CN115551875A (zh) 2020-05-05 2021-05-05 用于酪氨酸酶介导的位点特异性蛋白质缀合的系统和方法

Country Status (7)

Country Link
US (1) US20230192760A1 (https=)
EP (1) EP4146665A1 (https=)
JP (1) JP2023524288A (https=)
CN (1) CN115551875A (https=)
AR (1) AR122020A1 (https=)
TW (1) TW202207988A (https=)
WO (1) WO2021226247A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024153232A1 (zh) * 2023-01-19 2024-07-25 上海盛迪医药有限公司 酪氨酸酶介导的蛋白定点偶联及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119731192A (zh) * 2022-10-14 2025-03-28 香港中文大学 免疫球蛋白的位点特异性酪氨酸修饰

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111093712A (zh) * 2017-07-06 2020-05-01 国家科学研究中心 缀合度受控的生物缀合物、其制备方法及制备其的试剂
US20210308207A1 (en) * 2018-05-04 2021-10-07 Tagworks Pharmaceuticals B.V. Compounds comprising a linker for increasing transcyclooctene stability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085923A2 (en) 2001-04-19 2002-10-31 The Scripps Research Institute In vivo incorporation of unnatural amino acids
CN101048506B (zh) 2004-10-27 2013-06-26 斯克利普斯研究院 体内掺入非天然氨基酸的正交翻译组分
AU2007224019A1 (en) 2006-03-03 2007-09-13 California Institute Of Technology Site-specific incorporation of amino acids into molecules
EP2222341B1 (en) * 2007-11-21 2015-02-25 University Of Georgia Research Foundation, Inc. Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds
EP2882868B1 (en) * 2012-08-08 2019-07-31 H. Hoffnabb-La Roche Ag Increasing dynamic range for identifying multiple epitopes in cells
EP2974744A1 (en) * 2014-07-16 2016-01-20 Stichting Katholieke Universiteit Strain-promoted oxidation controlled cycloaddition with high reaction rate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111093712A (zh) * 2017-07-06 2020-05-01 国家科学研究中心 缀合度受控的生物缀合物、其制备方法及制备其的试剂
US20210308207A1 (en) * 2018-05-04 2021-10-07 Tagworks Pharmaceuticals B.V. Compounds comprising a linker for increasing transcyclooctene stability

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JORICK J. BRUINS 等: "Orthogonal, dual protein labelling by tandem cycloaddition of strained alkenes and alkynes to ortho-quinones and azides", CHEMICAL COMMUNICATIONS, vol. 54, no. 53, 31 December 2018 (2018-12-31), pages 1 - 3 *
张贤睿;罗惠鑫;樊新元;陈鹏;: "逆电子需求的狄尔斯-阿尔德反应在生物正交化学领域的发展与应用", 中国科学:化学, no. 10, 31 December 2020 (2020-12-31) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024153232A1 (zh) * 2023-01-19 2024-07-25 上海盛迪医药有限公司 酪氨酸酶介导的蛋白定点偶联及其应用

Also Published As

Publication number Publication date
AR122020A1 (es) 2022-08-03
JP2023524288A (ja) 2023-06-09
EP4146665A1 (en) 2023-03-15
TW202207988A (zh) 2022-03-01
US20230192760A1 (en) 2023-06-22
WO2021226247A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
US12214050B2 (en) C-terminal lysine conjugated immunoglobulins
US20250179141A1 (en) Activatable cytokine constructs and related compositions and methods
AU2017279352B2 (en) Lysine conjugated immunoglobulins
US20230192760A1 (en) Systems and methods for tyrosinase-mediated site-specific protein conjugation
JP2024164077A (ja) 翻訳後修飾が低減したペプチドリンカー
CN118355031A (zh) 抗糖-lamp1抗体及其用途
US11236386B2 (en) Method for labeling of aldehyde containing target molecules
TW202334186A (zh) 三聚體的可活化之細胞介素構築體及相關之組成物及方法
CN118354789A (zh) 抗糖-cMET抗体及其用途
US20220008551A1 (en) Polypeptide conjugates
HK40078127A (en) Systems and methods for tyrosinase-mediated site-specific protein conjugation
US20240400630A1 (en) Activatable cytokine constructs and related compositions and methods
EP4153619A2 (en) Site-specific conjugation of glycosylated monoclonal antibodies with transglutaminase
WO2023220617A2 (en) Compositions and methods for modification of cells
WO2025181697A1 (en) Bifunctional degraders of anti-pla2r antibody
CA3008645C (en) C-terminal lysine conjugated immunoglobulins
HK40044319A (en) Peptidic linker with reduced post-translational modification

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40078127

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination